Evoke Pharma EBITDA Margin 2012-2024 | EVOK
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Evoke Pharma (EVOK) over the last 10 years. The current EBITDA margin for Evoke Pharma as of September 30, 2024 is .
Evoke Pharma EBITDA Margin Historical Data |
Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
2024-09-30 |
$0.01B |
$-0.01B |
-60.00% |
2024-06-30 |
$0.01B |
$-0.01B |
-77.78% |
2024-03-31 |
$0.01B |
$-0.01B |
-114.29% |
2023-12-31 |
$0.01B |
$-0.01B |
-133.33% |
2023-09-30 |
$0.01B |
$-0.01B |
-160.00% |
2023-06-30 |
$0.00B |
$-0.01B |
-200.00% |
2023-03-31 |
$0.00B |
$-0.01B |
-266.67% |
2022-12-31 |
$0.00B |
$-0.01B |
-400.00% |
2022-09-30 |
$0.00B |
$-0.01B |
-800.00% |
2022-06-30 |
$0.00B |
$-0.01B |
-800.00% |
2022-03-31 |
$0.00B |
$-0.01B |
-800.00% |
2021-12-31 |
$0.00B |
$-0.01B |
-900.00% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.007B |
$0.005B |
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|